Submission Details
| 510(k) Number | K241787 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | June 21, 2024 |
| Decision Date | August 27, 2024 |
| Days to Decision | 67 days |
| Submission Type | Traditional |
| Review Panel | Chemistry (CH) |
| Summary | Summary PDF |
K241787 is an FDA 510(k) clearance for the CONTOUR? PLUS BLUE Blood Glucose Monitoring System; CONTOUR? NEXT GEN Blood Glucose Monitoring System, a System, Test, Blood Glucose, Over The Counter (Class II — Special Controls, product code NBW), submitted by Ascensia Diabetes Care U.S., Inc. (Parsippany, US). The FDA issued a Cleared decision on August 27, 2024, 67 days after receiving the submission on June 21, 2024. This device falls under the Chemistry review panel. Regulated under 21 CFR 862.1345.
| 510(k) Number | K241787 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | June 21, 2024 |
| Decision Date | August 27, 2024 |
| Days to Decision | 67 days |
| Submission Type | Traditional |
| Review Panel | Chemistry (CH) |
| Summary | Summary PDF |
| Product Code | NBW — System, Test, Blood Glucose, Over The Counter |
| Device Class | Class II — Special Controls |
| CFR Regulation | 21 CFR 862.1345 |